CRISPR director granted options on 13,000 shares
CRISPR Therapeutics AG director Maria Fardis received a grant of stock options, giving her the right to buy 13,000 common shares at an exercise price of $51.84 per share.
Rhea-AI Filing Summary
CRISPR Therapeutics AG director Maria Fardis received a grant of stock options, giving her the right to buy 13,000 common shares at an exercise price of $51.84 per share. These options were awarded as compensation, not through open-market buying or selling.
According to the vesting terms, the 13,000 options will vest in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 Annual Meeting, assuming she continues to provide service to the company or its subsidiaries.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 13,000 shares
Grant/Award
1 txn
Insider
Fardis Maria
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 13,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,000 contracts (Direct)
Footnotes (1)
- F1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Key Figures
Options granted: 13,000 options
Exercise price: $51.84 per share
Underlying shares: 13,000 common shares
+3 more
6 metrics
Options granted
13,000 options
Stock Option (Right to Buy) granted to Maria Fardis
Exercise price
<money>$51.84</money> per share
Conversion or exercise price of granted options
Underlying shares
13,000 common shares
Underlying security for the option grant
Total derivative holdings after grant
13,000 options
Total shares following transaction for this option award
Option expiration
<date>June 5, 2036</date>
Expiration date of the granted stock options
Vesting start date
<date>June 30, 2026</date>
First of 12 equal monthly vesting installments
Key Terms
Stock Option (Right to Buy), exercise price, vesting, Annual Meeting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion or exercise price of 51.8400 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"the options will vest and become exercisable in 12 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting financial
"the last installment vests on the earlier of one year anniversary or the 2027 Annual Meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CRISPR Therapeutics (CRSP) report for Maria Fardis?
CRISPR Therapeutics reported that director Maria Fardis received a grant of stock options for 13,000 common shares. These are compensation-related options, not open-market purchases or sales, and give her the right to buy shares at a fixed exercise price.
What is the exercise price of Maria Fardis’s CRISPR Therapeutics (CRSP) stock options?
The exercise price of Maria Fardis’s stock options is $51.84 per share. This means she can buy CRISPR Therapeutics common shares at that fixed price once the options vest and she chooses to exercise them, assuming she continues her service.
When do Maria Fardis’s CRISPR Therapeutics (CRSP) options vest?
The 13,000 stock options vest in 12 equal monthly installments, starting with the first installment on June 30, 2026. The final installment vests on the earlier of the one-year grant anniversary or the date of the 2027 Annual Meeting, subject to continued service.
Is Maria Fardis’s CRISPR Therapeutics (CRSP) Form 4 transaction a market purchase or sale?
The Form 4 transaction is not a market purchase or sale. It reflects a compensation-related grant of stock options coded as a grant or award, giving Maria Fardis rights to acquire shares in the future at a set exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
